Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2004;328:228 (24 January), doi:10.1136/bmj.328.7433.228-a
| The first 150 words of the full text of this article appear below. |
EDITORThe study of medical prescription of heroin by van den Brink et al should be interpreted with caution.1
Firstly, the selection of opiate dependent patients with at least four weeks of continuous treatment in the past five years does not define resistance to treatment with methadone treatment, but rather, early treatment intervention. This may explain the substantial treatment response to longer term methadone in the control group, where the only intervention is randomisation into a controlled trial.
Secondly, in such a study taking methadone and heroin dosage levels into account is crucial when evaluating clinical outcome; adequate doses of opiate replacement are critical to treatment success.2 Actual doses are reported only in the electronic version of the paper and show that doses of combined heroin and methadone in the heroin treatment groups are about 20% higher in terms of methadone equivalents compared with the control methadone only treatment
-->
Laurence J Reed, specialist registrar
spdpljr@iop.kcl.ac.uk, Bethlem Royal Hospital, South London and Maudsley NHS Trust, Beckenham, Kent BR3 3BX
Cornelis de Wet, specialist registrar, Jennifer Bearn, consultant
Bethlem Royal Hospital, South London and Maudsley NHS Trust, Beckenham, Kent BR3 3BX